Publication

Article

Digital Edition

Ophthalmology Times: October 1, 2021
Volume46
Issue 16

ARMOR study: Keeping pace with microbial resistance to antibiotics

Author(s):

Ongoing nationwide study looks at in vitro antibiotic resistance among isolates.

The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study has identified high levels of in vitro antibiotic resistance among ocular staphylococcal and pneumococcal pathogens, resistance that may affect treatment success


Reviewed by Penny Asbell, MD, FACS, MBA

The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study has identified high levels of in vitro antibiotic resistance among ocular staphylococcal and pneumococcal pathogens, resistance that may affect treatment success, according to Penny Asbell, MD, FACS, MBA, director of the Hamilton Eye Institute at the University of Tennessee Health Science Center.

The ARMOR study is an ongoing nationwide study examining in vitro antibiotic resistance among isolates that have been collected from ocular infections.

Between 2009 and 2018, 6091 ocular isolates were collected; specifically, Staphylococcus aureus (n = 2189), coagulase-negative staphylococci (n = 1745), Streptococcus pneumoniae (n = 590), Pseudomonas aeruginosa (n = 767), and Haemophilus influenzae (n = 780).

Related: VA and visual function go the way of ocular inflammation

The ocular isolates were obtained at the participating study sites nationwide and sent to a central laboratory for confirmation of bacterial identity and susceptibility testing.

The investigators also carried out a literature search for susceptibility data on the bacteria from ocular infections reported in other studies for comparison with 10-year ARMOR findings, according to Asbell.

According to investigators, the key findings from ARMOR include the following:

  • Staphylococci were resistant to azithromycin (60%-61%), methicillin (35%-51%), and ciprofloxacin (33%-34%).
  • S pneumoniae isolates were resistant to azithromycin and penicillin (32% and 36%, respectively). P aeruginosa and H influenzae resistance was low.
  • Multidrug resistance, defined as resistance to at least 1 antimicrobial drug in 3 or more drug classes, was especially prevalent among methicillin-resistant staphylococci.

A bright spot is that the prevalence of methicillin-resistant S aureus may be declining after reaching a peak from 2005 to 2015.

Related: Research: Similar endophthalmitis rates for generic, branded topical antibiotics

Based on their findings, the investigators concluded that “the ARMOR study showed high levels of in vitro antibiotic resistance among ocular staphylococcal and pneumococcal pathogens and were largely representative of those reported in smaller US surveillance studies.”

The investigators also suggest that surveillance data are relevant in that resistance to antibiotics may foretell treatment failure.

Penny Asbell, MD, FACS, MBA
E: pasbell@uthsc.edu
This article is adapted from Asbell’s presentation at the Women in Ophthalmology 2021 Summer Symposium. The ARMOR study is sponsored by Bausch + Lomb. Asbell was a consultant for Bausch Health US, LLC, for Grand Rounds presentation to Bausch & Lomb but has received no compensation for participation in this study.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
© 2025 MJH Life Sciences

All rights reserved.